Switch theme
Sign up to access all valuation multiples
Initiator Pharma AS is a research and development company engaged in the pharmaceutical development of drugs to be used for erectile dysfunction, depression, and pain. It Research is focused in the area of monoamine reuptake inhibitors.
2016
3
LTM Revenue $4.4M
LTM EBITDA $1.0M
$19.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Initiator Pharma has a last 12-month revenue (LTM) of $4.4M and a last 12-month EBITDA of $1.0M.
In the most recent fiscal year, Initiator Pharma achieved revenue of n/a and an EBITDA of -$1.5M.
Initiator Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Initiator Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $4.4M | XXX | -$1.1M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $1.0M | XXX | -$1.5M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | n/a | XXX | XXX | XXX |
| EBIT | $1.0M | XXX | -$1.5M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | $0.8M | XXX | -$1.3M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Initiator Pharma's stock price is SEK 4 (or $0).
Initiator Pharma has current market cap of SEK 206M (or $21.3M), and EV of SEK 187M (or $19.3M).
See Initiator Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.3M | $21.3M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Initiator Pharma has market cap of $21.3M and EV of $19.3M.
Initiator Pharma's trades at n/a EV/Revenue multiple, and -12.9x EV/EBITDA.
Equity research analysts estimate Initiator Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Initiator Pharma has a P/E ratio of 37.3x.
See valuation multiples for Initiator Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.3M | XXX | $21.3M | XXX | XXX | XXX |
| EV (current) | $19.3M | XXX | $19.3M | XXX | XXX | XXX |
| EV/Revenue | 6.4x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 27.5x | XXX | -12.9x | XXX | XXX | XXX |
| EV/EBIT | 27.5x | XXX | -12.9x | XXX | XXX | XXX |
| EV/Gross Profit | 6.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 37.3x | XXX | -15.9x | XXX | XXX | XXX |
| EV/FCF | 17.6x | XXX | -15.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInitiator Pharma's last 12 month revenue growth is 42%
Initiator Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.1M for the same period.
Initiator Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Initiator Pharma's rule of X is 127% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Initiator Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 89% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 127% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Initiator Pharma acquired XXX companies to date.
Last acquisition by Initiator Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Initiator Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Initiator Pharma founded? | Initiator Pharma was founded in 2016. |
| Where is Initiator Pharma headquartered? | Initiator Pharma is headquartered in Sweden. |
| How many employees does Initiator Pharma have? | As of today, Initiator Pharma has 3 employees. |
| Is Initiator Pharma publicy listed? | Yes, Initiator Pharma is a public company listed on STO. |
| What is the stock symbol of Initiator Pharma? | Initiator Pharma trades under INIT ticker. |
| When did Initiator Pharma go public? | Initiator Pharma went public in 2017. |
| Who are competitors of Initiator Pharma? | Similar companies to Initiator Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Initiator Pharma? | Initiator Pharma's current market cap is $21.3M |
| What is the current revenue of Initiator Pharma? | Initiator Pharma's last 12 months revenue is $4.4M. |
| What is the current revenue growth of Initiator Pharma? | Initiator Pharma revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Initiator Pharma? | Current revenue multiple of Initiator Pharma is 6.4x. |
| Is Initiator Pharma profitable? | Yes, Initiator Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Initiator Pharma? | Initiator Pharma's last 12 months EBITDA is $1.0M. |
| What is Initiator Pharma's EBITDA margin? | Initiator Pharma's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Initiator Pharma? | Current EBITDA multiple of Initiator Pharma is 27.5x. |
| What is the current FCF of Initiator Pharma? | Initiator Pharma's last 12 months FCF is $1.6M. |
| What is Initiator Pharma's FCF margin? | Initiator Pharma's last 12 months FCF margin is 36%. |
| What is the current EV/FCF multiple of Initiator Pharma? | Current FCF multiple of Initiator Pharma is 17.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
